Salix Pharmaceuticals Receives Consensus Rating of “Hold” from Analysts (NASDAQ:SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP) has received an average rating of “Hold” from the sixteen analysts that are presently covering the stock, AnalystRatings.Net reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $90.80.
A number of analysts have recently weighed in on SLXP shares. Analysts at Roth Capital raised their price target on shares of Salix Pharmaceuticals from $106.00 to $110.00 in a research note on Friday, February 7th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note on Monday, January 20th. They now have a $103.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Salix Pharmaceuticals to $115.00 in a research note on Friday, January 17th.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.